PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD

Barbara Gross,Michal Pawlak,Philippe Lefebvre,Bart Staels
DOI: https://doi.org/10.1038/nrendo.2016.135
2016-09-16
Nature Reviews Endocrinology
Abstract:Key PointsObesity might be combated by reducing fat storage in white adipose tissue (WAT), increasing energy expenditure through adaptive thermogenesis in brown adipose tissue (BAT) and/or the browning of WATIn mouse models the three peroxisome proliferator-activated receptor (PPAR) isotypes regulate adaptive thermogenesis in BAT via distinct mechanisms; PPARα and PPARγ ligands also promote WAT browning, but the relevance of these findings to human pathology is unknownPPAR ligands reduce obesity-associated comorbidities by acting on fat storage capacity of WAT and fat burning in BAT and/or peripheral tissues, thereby reducing ectopic fat overloadPPARα and PPARγ ligands are clinically used for the treatment of dyslipidaemia and insulin resistance, respectively; in preclinical models, PPARβ/δ agonists also improve atherogenic dyslipidaemia and insulin resistanceClinical trials using PPARγ agonists show favourable effects in patients with nonalcoholic steatohepatitis, but the results are so far inconclusiveThe current challenge is to develop potent PPAR agonists without adverse effects; agonists targeting two or more PPARs that have a partial or selective gene activation pattern represent potential therapeutic approaches
endocrinology & metabolism
What problem does this paper attempt to address?